Cytosorbents Corp (CTSO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cytosorbents Corporation on July 26, 2024, with a report date of August 1, 2024. The filing addresses the Company's status regarding its listing on The Nasdaq Stock Market LLC (Nasdaq Capital Market).
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement. Previously, on May 22, 2024, the Company received notice of non-compliance because its stock closed below $1.00 per share for 30 consecutive business days. The Company was granted 180 calendar days to regain compliance. The filing confirms that from July 12, 2024, to July 25, 2024, the closing bid price was at least $1.00 per share for 10 consecutive business days, satisfying the requirement.
Outlook, Risks, and Management Commentary
Nasdaq has officially considered the matter closed. The Company issued a press release on August 1, 2024, announcing this regained compliance. No new risks, contingencies, or unusual items were disclosed in this specific filing beyond the resolution of the prior listing deficiency.
Investor Verification Checklist
- Verify the current trading price of CTSO to ensure it remains above the $1.00 threshold to maintain compliance.
- Review the press release dated August 1, 2024 (Exhibit 99.1) for any additional operational context.
- Monitor future filings for any recurrence of bid price issues or other Nasdaq listing deficiencies.